Table 4:
Assessing the performance of MMB-eGFR equation (vs mGFR) in patients of African or Caribbean origin and in non-Black patients, compared with those of equations based on demographic data.
| Mean bias (95% CI) (mL/min/1.73 m2) | SD of the bias (mL/min/1.73 m2) | Accuracy within 20% (95% CI) (%) | Accuracy within 30% (95% CI) (%) | Lin's CCC (95% CI) | |
|---|---|---|---|---|---|
| Patients with African or Caribbean ancestry (n = 34: V1 = 14; V2 = 20) | |||||
| MMB-eGFR | −3.2 (−7.7 to 1.4) | 13.5 | 79.4 (65.8 to 93.0) | 91.2 (81.6.to 100) | 0.88 (0.78 to 0.94) |
| CKD-EPICrCr2009 no-race | −4.4 (−8.5 to −0.3) | 12.3 | 70.6 (55.3 to 85.9) | 91.2 (81.6.to 100) | 0.90 (0.82 to 0.95) |
| CKD-EPICrCr2009 race | 6.6 (1.6 to 11.6) | 14.8 | 76.5 (62.2 to 90.7) | 79.4 (65.8 to 93.0) | 0.87 (0.78 to 0.93) |
| CKD-EPICr2021 | −1.4 (−5.5 to 2.6) | 12.2 | 73.5 (58.7 to 88.4) | 94.1 (91.1 to 100) | 0.92 (0.84 to 0.96) |
| EKFC | −6.0 (−9.8 to −2.2) | 11.4 | 73.5 (58.7 to 88.4) | 91.2 (81.6 to 100) | 0.90 (0.81 to 0.95) |
| EKFC with African-European Q values | 0.6 (−3.3 to 4.4) | 11.4 | 76.5 (62.2 to 90.7) | 91.2 (81.6 to 100) | 0.92 (0.85 to 0.96) |
| CKD-EPICys (n = 33) | 2.4 (−2.4 to 7.2) | 14.1 | 60.6 (43.9 to 77.3) | 90.9 (81.1 to 100) | 0.90 (0.82 to 0.94) |
| Mean MMB-eGFR/CKD-EPICys (n = 33) | −0.3 (−3.9 to 3.2) | 10.6 | 81.8 (68.7 to 95.0) | 100 | 0.94 (0.88 to 0.97) |
| CKD-EPICr-Cys2021 (n = 33) | 2.7 (−1.5 to 7.0) | 12.5 | 75.8 (58.4 to 93.2) | 93.9 (85.8 to 100) | 0.92 (0.85 to 0.95) |
| FAScombi (n = 33) | −1.4 (−5.5 to 2.8) | 12.1 | 72.7 (57.5 to 87.9) | 93.9 (85.8 to 100) | 0.91 (0.84 to 0.95) |
| Non-Black patients (n = 135: V1 = 100; V2 = 35) | |||||
| MMB-eGFR | −1.0 (−3.4 to 1.3) | 14.0 | 77.8 (70.8 to 84.8) | 91.1 (86.3 to 95.9) | 0.85 (0.80 to 0.89) |
| CKD-EPICr2009 | 3.8 (1.3 to 6.3) | 14.9 | 76.3 (69.1 to 83.5) | 91.1 (86.3 to 95.9) | 0.83 (0.76 to 0.87) |
| CKD-EPICr2021 | 6.9 (4.4 to 9.4) | 14.8 | 68.9 (61.1 to 76.7) | 89.6 (84.5 to 94.8) | 0.81 (0.74 to 0.86) |
| EKFC | 0.3 (−2.1 to 2.7) | 14.3 | 79.3 (72.4 to 86.1) | 94.1 (90.1 to 98.1) | 0.84 (0.78 to 0.88) |
| CKD-EPICys (n = 131) | 1.4 (−1.2 to 4.0) | 15.3 | 67.9 (60.0 to 75.9) | 86.3 (80.4 to 92.2) | 0.85 (0.80 to 0.89) |
| Mean MMB-eGFR/CKD-EPICys (n = 131) | 0.2 (−1.8 to 2.1) | 11.2 | 81.7 (75.1 to 88.3) | 97.0 (94.0 to 99.9) | 0.91 (0.87 to 0.93) |
| CKD-EPICr-Cys2021 (n = 131) | 6.5 (4.2 to 8.7) | 13.2 † | 69.5 (61.6 to 77.4)† | 88.6 (83.1 to 94.0)† | 0.86 (0.81 to 0.89) |
| FAScombi (n = 131) | 2.0 (−0.6 to 4.6) | 15.2 † | 76.3 (69.1 to 83.6) | 88.6 (83.1 to 94.0)† | 0.84 (0.79 to 0.88) |
For CKD-EPICr2009, CKD-EPICr2021, EKFC and CKD-EPICys, P-values were calculated against MMB-eGFR in each population. *P < .05. For CKD-EPICr-Cys2021 and FAScombi, P-values were calculated against Mean MMB-eGFR/CKD-EPICys, in each population. †P < .05. The precision (SD of the bias) comparison was performed with Pitman's test. Accuracy comparison was performed with McNemar's test.
CKD-EPICr2009 no-race, CKD-EPICr2009 without African American correction factor; CKD-EPICr2009 race, CKD-EPICr2009 with African American correction factor; Lin's CCC, Lin's concordance correlation coefficient; V1/V2, validation population 1/2.